<code id='C2896ACB71'></code><style id='C2896ACB71'></style>
    • <acronym id='C2896ACB71'></acronym>
      <center id='C2896ACB71'><center id='C2896ACB71'><tfoot id='C2896ACB71'></tfoot></center><abbr id='C2896ACB71'><dir id='C2896ACB71'><tfoot id='C2896ACB71'></tfoot><noframes id='C2896ACB71'>

    • <optgroup id='C2896ACB71'><strike id='C2896ACB71'><sup id='C2896ACB71'></sup></strike><code id='C2896ACB71'></code></optgroup>
        1. <b id='C2896ACB71'><label id='C2896ACB71'><select id='C2896ACB71'><dt id='C2896ACB71'><span id='C2896ACB71'></span></dt></select></label></b><u id='C2896ACB71'></u>
          <i id='C2896ACB71'><strike id='C2896ACB71'><tt id='C2896ACB71'><pre id='C2896ACB71'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:comprehensive    Page View:74477
          The FDA building -- First Opinion coverage from STAT
          Adobe

          WASHINGTON — The Food and Drug Administration’s top cancer drug regulator doesn’t always ask for permission before taking on big initiatives.

          Richard Pazdur, director of the FDA Oncology Center of Excellence, hates bureaucracy. It stifles his ideas for getting treatments to cancer patients faster — of which there are many.

          advertisement

          To cut through that bureaucracy, Pazdur has a trick: “Don’t tell anybody,” he said to laughter at a meeting of the advocacy group Friends of Cancer Research Tuesday.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          George Santos makes 1st court appearance after pleading not guilty to 13 counts
          George Santos makes 1st court appearance after pleading not guilty to 13 counts

          1:57GeorgeSantosarrivesatfederalcourtJune30,2023,inCentralIslip,N.Y.JohnMinchillo/APRep.GeorgeSantos

          read more
          Apellis safety probe of eye disease drug centers on injection needle
          Apellis safety probe of eye disease drug centers on injection needle

          AlexHogan/STATApellisPharmaceuticalssaidTuesdaythatithadidentified“internalstructuralvariations”inat

          read more
          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more

          AstraZeneca challenges Medicare drug negotiation program

          AstraZenecaissuingtheBidenadministrationtostopanewMedicaredrugpricenegotiationprogram.AdobeWASHINGTO